Nicoletta Smirne
Research Subjects
Research Interests
Nicoletta Smirne has a total of 275 co-authors. Here are the top co-authors by number of shared publications:
- Amalia Cecilia Bruni
Regional Neurogenetic Centre, ASP Catanzaro, Lamezia Terme, Italy
25 shared publications - Maria Anfossi
Regional Neurogenetic Centre (CRN), ASP Catanzaro, Lamezia Terme, Italy
22 shared publications - Rosanna Colao
Regional Neurogenetic Centre (CRN), ASP Catanzaro, Lamezia Terme, Italy
22 shared publications - Sabrina Anna Maria Curcio
Regional Neurogenetic Centre (CRN), ASP Catanzaro, Lamezia Terme, Italy
18 shared publications Gianfranco Puccio
Regional Neurogenetic Centre ASP-CZ, Lamezia Terme (CZ), Italy
17 shared publicationsFrancesca Frangipane
Regional Neurogenetic Centre ASP-CZ, Lamezia Terme (CZ), Italy
16 shared publications
Latest Publications
- 9 January 2018
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 61 (3) , 1179-1187
Frequency of Cardiovascular Genetic Risk Factors in a Calabrian Population and Their Effects on Dementia
Background: Several genetic variants playing a key role in cholesterol levels, blood pressure, and vascular dysfunction influence the risk of Alzheimer’s disease (AD) and vascular dementia (VaD). The many meta-analysis studies carried out on large numbers of samples in different populations have not provided clear results to date, because a trans-ethnic shift of risk genotypes in different populations is often observed. Objectives: To determine genotypes allele frequencies of the polymorphisms most frequently identified to be correlated with cardio-cerebrovascular disease and AD in a Southern Italy population and to investigate their possible association with dementia. Methods: The genotype and allele frequencies of 13 cardio-cerebrovascular risk polymorphisms were assessed and their possible association with dementia was investigated in a case-control study, including 221 consecutive unrelated subjects diagnosed with dementia (120 subjects affected by AD, 55 by frontotemporal dementia, and 33 by vascular dementia) and 218 matched controls of Calabrian origin. Results: Carriers of at least one APOE ɛ4 allele resulted to be at higher risk of AD [OR(95% CI) = 2.721(1.477–5.011)] and VaD [OR(95% CI) = 6.205(2.356–16.342)] compared to non-carriers. Individuals with the IV genotype of the CETP polymorphism were more likely to have AD [OR(95% CI) = 2.427(1.364–4.319)] and VaD [OR(95% CI) = 3.649(1.455–9.152)] compared to subjects with the II-VV genotypes. Conclusion: CETP I405V polymorphism is likely a risk factor for AD and VaD in our cohort, independent of APOE ɛ4 status. Unmodifiable genetic risk factors should be taken into account to promote a healthy lifestyle to prevent dementia.
- 9 January 2018
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 61 (3) , 1179-1187
Frequency of Cardiovascular Genetic Risk Factors in a Calabrian Population and Their Effects on Dementia
Background: Several genetic variants playing a key role in cholesterol levels, blood pressure, and vascular dysfunction influence the risk of Alzheimer’s disease (AD) and vascular dementia (VaD). The many meta-analysis studies carried out on large numbers of samples in different populations have not provided clear results to date, because a trans-ethnic shift of risk genotypes in different populations is often observed. Objectives: To determine genotypes allele frequencies of the polymorphisms most frequently identified to be correlated with cardio-cerebrovascular disease and AD in a Southern Italy population and to investigate their possible association with dementia. Methods: The genotype and allele frequencies of 13 cardio-cerebrovascular risk polymorphisms were assessed and their possible association with dementia was investigated in a case-control study, including 221 consecutive unrelated subjects diagnosed with dementia (120 subjects affected by AD, 55 by frontotemporal dementia, and 33 by vascular dementia) and 218 matched controls of Calabrian origin. Results: Carriers of at least one APOE ɛ4 allele resulted to be at higher risk of AD [OR(95% CI) = 2.721(1.477–5.011)] and VaD [OR(95% CI) = 6.205(2.356–16.342)] compared to non-carriers. Individuals with the IV genotype of the CETP polymorphism were more likely to have AD [OR(95% CI) = 2.427(1.364–4.319)] and VaD [OR(95% CI) = 3.649(1.455–9.152)] compared to subjects with the II-VV genotypes. Conclusion: CETP I405V polymorphism is likely a risk factor for AD and VaD in our cohort, independent of APOE ɛ4 status. Unmodifiable genetic risk factors should be taken into account to promote a healthy lifestyle to prevent dementia.
- 28 November 2017
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 61 (1) , 251-257
Prevalence of Delirium in a Population of Elderly Outpatients with Dementia: A Retrospective Study
Background: Delirium is a multifactorial geriatric syndrome and often occurs in patients with cognitive impairment. It also remains under-recognized, specifically in elderly outpatients, because signs of delirium might overlap with symptoms of dement
- 28 November 2017
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 61 (1) , 251-257
Prevalence of Delirium in a Population of Elderly Outpatients with Dementia: A Retrospective Study
Background: Delirium is a multifactorial geriatric syndrome and often occurs in patients with cognitive impairment. It also remains under-recognized, specifically in elderly outpatients, because signs of delirium might overlap with symptoms of dement
- 1 August 2017
- Published by Elsevier in Neurobiology of Aging
- Vol. 56, 213.e7-213.e12
The novel PSEN1 M84V mutation associated to frontal dysexecutive syndrome, spastic paraparesis, and cerebellar atrophy in a dominant Alzheimer's disease family
- 1 August 2017
- Published by Elsevier in Neurobiology of Aging
- Vol. 56, 213.e7-213.e12
The novel PSEN1 M84V mutation associated to frontal dysexecutive syndrome, spastic paraparesis, and cerebellar atrophy in a dominant Alzheimer's disease family
- 6 December 2016
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 55 (3) , 1249-1259
Role of Niemann-Pick Type C Disease Mutations in Dementia
Background: Several neurological and systemic diseases can cause dementia, beyond Alzheimer’s disease. Rare genetic causes are often responsible for dementia with atypical features. Recently, mutations causative for Niemann-Pick type C disease (NPC)
- 6 December 2016
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 55 (3) , 1249-1259
Role of Niemann-Pick Type C Disease Mutations in Dementia
Background: Several neurological and systemic diseases can cause dementia, beyond Alzheimer’s disease. Rare genetic causes are often responsible for dementia with atypical features. Recently, mutations causative for Niemann-Pick type C disease (NPC)
- 29 November 2016
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 56 (1) , 239-248
Short-Term Response is not Predictive of Long-Term Response to Acetylcholinesterase Inhibitors in Old Age Subjects with Alzheimer’s Disease: A “Real World” Study
Background: Most of clinical guidelines recommend discontinuing treatment with cholinesterase inhibitors (ChEIs) in patients with Alzheimer’s disease (AD) who do not show an initial response to therapy as evaluated with the Mini-Mental State Examination (MMSE) scale. However, understanding the relationship between the initial response to ChEI treatment and the subsequent course of the disease is extremely important in clinical practice, but evidence is limited, particularly in the old-old population. Objective: We aimed at investigating the relationship between short-term and long-term response to ChEI therapy in old age subjects with AD in a “real life” setting. Methods: This is a retrospective longitudinal study of 628 old age subjects (≥65 years old) with AD and treated with ChEIs over three year follow-up. The sample was divided into “young-old” (≤75 years) and “old-old” (≥76 years) according to age, and as “responder” and “non-responder” according to the initial (i.e., after three months) response to treatment. Cognitive and functional evaluation was performed by means of MMSE and ADL/IADL, respectively. Results: In the long run, subjects considered as non-responders showed a lower rate of cognitive decline as compared with responders, with a mean annual decline at MMSE of 1.0 point versus 1.6 points ( p < 0.0001), respectively. Old-old non-responders had a slower rate of cognitive ( p < 0.0001) and functional decline ( p < 0.0001) as compared with responders after three years of observation. Conclusion: Discontinuing ChEI treatment solely for the absence of an initial response is not appropriate, especially in old-old subjects.
- 29 November 2016
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 56 (1) , 239-248
Short-Term Response is not Predictive of Long-Term Response to Acetylcholinesterase Inhibitors in Old Age Subjects with Alzheimer’s Disease: A “Real World” Study
Background: Most of clinical guidelines recommend discontinuing treatment with cholinesterase inhibitors (ChEIs) in patients with Alzheimer’s disease (AD) who do not show an initial response to therapy as evaluated with the Mini-Mental State Examination (MMSE) scale. However, understanding the relationship between the initial response to ChEI treatment and the subsequent course of the disease is extremely important in clinical practice, but evidence is limited, particularly in the old-old population. Objective: We aimed at investigating the relationship between short-term and long-term response to ChEI therapy in old age subjects with AD in a “real life” setting. Methods: This is a retrospective longitudinal study of 628 old age subjects (≥65 years old) with AD and treated with ChEIs over three year follow-up. The sample was divided into “young-old” (≤75 years) and “old-old” (≥76 years) according to age, and as “responder” and “non-responder” according to the initial (i.e., after three months) response to treatment. Cognitive and functional evaluation was performed by means of MMSE and ADL/IADL, respectively. Results: In the long run, subjects considered as non-responders showed a lower rate of cognitive decline as compared with responders, with a mean annual decline at MMSE of 1.0 point versus 1.6 points ( p < 0.0001), respectively. Old-old non-responders had a slower rate of cognitive ( p < 0.0001) and functional decline ( p < 0.0001) as compared with responders after three years of observation. Conclusion: Discontinuing ChEI treatment solely for the absence of an initial response is not appropriate, especially in old-old subjects.
- 11 October 2016
- Published by Springer Nature in Journal of Neurology
- Vol. 263 (12) , 2494-2498
Angela R.: a familial Alzheimer’s disease case in the days of Auguste D.
- 11 October 2016
- Published by Springer Nature in Journal of Neurology
- Vol. 263 (12) , 2494-2498
Angela R.: a familial Alzheimer’s disease case in the days of Auguste D.
- 25 February 2016
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 51 (4) , 1265-1274
The Genetic Variability of UCP4 Affects the Individual Susceptibility to Late-Onset Alzheimer’s Disease and Modifies the Disease’s Risk in APOE- ɛ 4 Carriers
Uncoupling proteins (UCPs) are a group of five mitochondrial inner membrane transporters with a tissue specific expression that uncouple biofuel oxidation from ATP synthesis and function as regulators of energy homeostasis and antioxidants. Previous data suggested that neuronal UCPs (UCP2, UCP4, and UCP5) can directly influence synaptic plasticity, neurotransmission, and neurodegenerative processes, and have a crucial role in the function and protection of the central nervous system. In fact, it has been observed that the expression of neuronal UCPs significantly decreases in Alzheimer’s disease (AD) patients. Here we analyzed the variability of UCP2 , - 3 , - 4 , and 5 genes in sporadic and familial cases ( n = 465) of late-onset AD (LOAD) with respect to healthy controls ( n = 442). We showed that a genetic variant in the human UCP4 , rs9472817, not only significantly affects the individual susceptibility to LOAD, but also modulates the effect of APOE - ɛ4 on AD risk. In fact, rs9472817-C allele was significantly more frequent in both groups of patients with respect to the control group ( p = 6.934 * 10 –4 for familial and p = 1.033 * 10 –3 for sporadic cases). In addition, gene-gene interaction analysis revealed that the effect of APOE- ɛ 4 allele on LOAD risk was doubled in homozygote CC subjects; conversely, the risk conferred by the APOE- ɛ 4 allele was annulled in subjects with two copies of the G allele. Our findings are further evidence that the efficiency in mitochondrial energy metabolism and oxidative stress are important factors in AD pathogenesis.
- 25 February 2016
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 51 (4) , 1265-1274
The Genetic Variability of UCP4 Affects the Individual Susceptibility to Late-Onset Alzheimer’s Disease and Modifies the Disease’s Risk in APOE- ɛ 4 Carriers
Uncoupling proteins (UCPs) are a group of five mitochondrial inner membrane transporters with a tissue specific expression that uncouple biofuel oxidation from ATP synthesis and function as regulators of energy homeostasis and antioxidants. Previous data suggested that neuronal UCPs (UCP2, UCP4, and UCP5) can directly influence synaptic plasticity, neurotransmission, and neurodegenerative processes, and have a crucial role in the function and protection of the central nervous system. In fact, it has been observed that the expression of neuronal UCPs significantly decreases in Alzheimer’s disease (AD) patients. Here we analyzed the variability of UCP2 , - 3 , - 4 , and 5 genes in sporadic and familial cases ( n = 465) of late-onset AD (LOAD) with respect to healthy controls ( n = 442). We showed that a genetic variant in the human UCP4 , rs9472817, not only significantly affects the individual susceptibility to LOAD, but also modulates the effect of APOE - ɛ4 on AD risk. In fact, rs9472817-C allele was significantly more frequent in both groups of patients with respect to the control group ( p = 6.934 * 10 –4 for familial and p = 1.033 * 10 –3 for sporadic cases). In addition, gene-gene interaction analysis revealed that the effect of APOE- ɛ 4 allele on LOAD risk was doubled in homozygote CC subjects; conversely, the risk conferred by the APOE- ɛ 4 allele was annulled in subjects with two copies of the G allele. Our findings are further evidence that the efficiency in mitochondrial energy metabolism and oxidative stress are important factors in AD pathogenesis.
- 2 June 2015
- Published by Wolters Kluwer Health in Neurology
- Vol. 84 (22) , 2266-2273
Homozygous carriers of APP A713T mutation in an autosomal dominant Alzheimer disease family
Objective: To report, for the first time, a large autosomal dominant Alzheimer disease (AD) family in which the APP A713T mutation is present in the homozygous and heterozygous state. To date, the mutation has been reported as dominant, and in the heterozygous state associated with familial AD and cerebrovascular lesions. Methods: The family described here has been genealogically reconstructed over 6 generations dating back to the 19th century. Plasma β-amyloid peptide was measured. Sequencing of causative AD genes was performed. Results: Twenty-one individuals, all but 1 born from 2 consanguineous unions, were studied: 8 were described as affected through history, 5 were studied clinically and genetically, and 8 were asymptomatic at-risk subjects. The A713T mutation was detected in the homozygous state in 3 patients and in the heterozygous state in 8 subjects (6 asymptomatic and 2 affected). Conclusions: Our findings, also supported by the β-amyloid plasma assay, confirm (1) the pathogenic role of the APP A713T mutation, (2) the specific phenotype (AD with cerebrovascular lesions) associated with this mutation, and (3) the large span of age at onset, not influenced by APOE, TOMM40, and TREM2 genes. No substantial differences concerning clinical phenotype were evidenced between heterozygous and homozygous patients, in line with the classic definition of dominance. Therefore, in this study, AD followed the classic definition of a dominant disease, contrary to that reported in a previously described AD family with recessive APP mutation. This confirms that genetic AD may be considered a disease with dominant and recessive traits of inheritance.
- 2 June 2015
- Published by Wolters Kluwer Health in Neurology
- Vol. 84 (22) , 2266-2273
Homozygous carriers of APP A713T mutation in an autosomal dominant Alzheimer disease family
Objective: To report, for the first time, a large autosomal dominant Alzheimer disease (AD) family in which the APP A713T mutation is present in the homozygous and heterozygous state. To date, the mutation has been reported as dominant, and in the heterozygous state associated with familial AD and cerebrovascular lesions. Methods: The family described here has been genealogically reconstructed over 6 generations dating back to the 19th century. Plasma β-amyloid peptide was measured. Sequencing of causative AD genes was performed. Results: Twenty-one individuals, all but 1 born from 2 consanguineous unions, were studied: 8 were described as affected through history, 5 were studied clinically and genetically, and 8 were asymptomatic at-risk subjects. The A713T mutation was detected in the homozygous state in 3 patients and in the heterozygous state in 8 subjects (6 asymptomatic and 2 affected). Conclusions: Our findings, also supported by the β-amyloid plasma assay, confirm (1) the pathogenic role of the APP A713T mutation, (2) the specific phenotype (AD with cerebrovascular lesions) associated with this mutation, and (3) the large span of age at onset, not influenced by APOE, TOMM40, and TREM2 genes. No substantial differences concerning clinical phenotype were evidenced between heterozygous and homozygous patients, in line with the classic definition of dominance. Therefore, in this study, AD followed the classic definition of a dominant disease, contrary to that reported in a previously described AD family with recessive APP mutation. This confirms that genetic AD may be considered a disease with dominant and recessive traits of inheritance.
- 1 November 2014
- Published by Elsevier in Neurobiology of Aging
- Vol. 35 (11) , 2657.e7-2657.e11
Novel N-terminal domain mutation in prion protein detected in 2 patients diagnosed with frontotemporal lobar degeneration syndrome
- 1 November 2014
- Published by Elsevier in Neurobiology of Aging
- Vol. 35 (11) , 2657.e7-2657.e11
Novel N-terminal domain mutation in prion protein detected in 2 patients diagnosed with frontotemporal lobar degeneration syndrome
- 1 July 2014
- Published by Elsevier in The Lancet Neurology
- Vol. 13 (7) , 686-699
Frontotemporal dementia and its subtypes: a genome-wide association study
- 1 July 2014
- Published by Elsevier in The Lancet Neurology
- Vol. 13 (7) , 686-699
Frontotemporal dementia and its subtypes: a genome-wide association study